Gael Roue

Gael Roue

Company: Josep Carreras Leukaemia Research Institute

Job title: Head of the Lymphoma Translational Research Group


Activity of the Novel Bispecific CD47-CD19 Antibody, TG-1801, In Preclinical Models of B-Cell Non-Hodgkin Lymphoma 1:30 pm

TG-1801 is a novel bispecific antibody specifically targeting CD47 in CD19+ cells. TG-1801 facilitates CD20-mediated ADCC and ADCP in in vivo and in vitro models of Burkitt lymphoma by promoting the infiltration of effector cells (NK and macrophages) Phase 1 is ongoing in histologically confirmed B-cell lymphoma relapsed or refractory to prior standard therapyRead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.